Marie-Claire Gubler

Marie-Claire Gubler

Auto-generated profile, based on publicly available information

Marie-Claire Gubler

Hôpital Necker Enfants Malades

Research Focus & Metrics

Academic Career Length

60Years (1967-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
NBNicolas Boute
Nicolas Boute
OGOlivier Gribouval
Olivier Gribouval
SRSéverine Roselli
Séverine Roselli
FBFrance Benessy
France Benessy
HLHyunjoo Lee
Hyunjoo Lee
CACorinne Antignac
Corinne Antignac

2 July 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MMMichael Mauer
Michael Mauer
BZBernard Zinman
Bernard Zinman
RGRobert Gardiner
Robert Gardiner
SSSamy Suissa
Samy Suissa
ASAlan Sinaiko
Alan Sinaiko
RKRonald Klein
Ronald Klein
Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin–angiotensin system. We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years. The primary end point was a change in the fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens. The retinopathy end point was a progression on a retinopathy severity scale of two steps or more. Intention-to-treat analysis was performed with the use of linear regression and logistic-regression models. A total of 90% and 82% of patients had complete renal-biopsy and retinopathy data, respectively. Change in mesangial fractional volume per glomerulus over the 5-year period did not differ significantly between the placebo group (0.016 units) and the enalapril group (0.005, P=0.38) or the losartan group (0.026, P=0.26), nor were there significant treatment benefits for other biopsy-assessed renal structural variables. The 5-year cumulative incidence of microalbuminuria was 6% in the placebo group; the incidence was higher with losartan (17%, P=0.01 by the log-rank test) but not with enalapril (4%, P=0.96 by the log-rank test). As compared with placebo, the odds of retinopathy progression by two steps or more was reduced by 65% with enalapril (odds ratio, 0.35; 95% confidence interval [CI], 0.14 to 0.85) and by 70% with losartan (odds ratio, 0.30; 95% CI, 0.12 to 0.73), independently of changes in blood pressure. There were three biopsy-related serious adverse events that completely resolved. Chronic cough occurred in 12 patients receiving enalapril, 6 receiving losartan, and 4 receiving placebo. Early blockade of the renin–angiotensin system in patients with type 1 diabetes did not slow nephropathy progression but slowed the progression of retinopathy. (ClinicalTrials.gov number, NCT00143949.)

1 December 1997 in Nature Genetics
Verified
Journal Article
Closed access
SBSandrine Barbaux
Sandrine Barbaux
PNPatrick Niaudet
Patrick Niaudet
MGMarie-Claire Gubler
Marie-Claire Gubler
JGJean-Pierre Grünfeld
Jean-Pierre Grünfeld
FJFrancis Jaubert
Francis Jaubert
CFClaire Nihoul Fékété
Claire Nihoul Fékété

1 August 2001 in Cell
Verified
Journal Article
Closed access
AHAnnette Hammes
Annette Hammes
JGJian-Kan Guo
Jian-Kan Guo
GLGudrun Lutsch
Gudrun Lutsch
JLJoerg-Robert Leheste
Joerg-Robert Leheste
DLDanilo Landrock
Danilo Landrock
ASAndreas Schedl
Andreas Schedl

10 June 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MDMarion Delous
Marion Delous
LBLekbir Baala
Lekbir Baala
RSRémi Salomon
Rémi Salomon
CLChristine Laclef
Christine Laclef
JVJeanette Vierkotten
Jeanette Vierkotten
SSSophie Saunier
Sophie Saunier

31 March 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MLMathieu Lemaire
Mathieu Lemaire
VFVéronique Frémeaux-Bacchi
Véronique Frémeaux-Bacchi
FSFranz Schaefer
Franz Schaefer
MCMurim Choi
Murim Choi
WTWai Ho Tang
Wai Ho Tang
RLRichard P Lifton
Richard P Lifton
Richard Lifton, Véronique Frémeaux-Bacchi and colleagues report that recessive mutations in DGKE cause atypical hemolytic-uremic syndrome with an early age of onset progressing to chronic kidney disease. The authors propose that loss of DGKE results in a prothrombotic state that underlies disease pathogenesis. Pathologic thrombosis is a major cause of mortality. Hemolytic-uremic syndrome (HUS) features episodes of small-vessel thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia and renal failure1. Atypical HUS (aHUS) can result from genetic or autoimmune factors2 that lead to pathologic complement cascade activation3. Using exome sequencing, we identified recessive mutations in DGKE (encoding diacylglycerol kinase ɛ) that co-segregated with aHUS in nine unrelated kindreds, defining a distinctive Mendelian disease. Affected individuals present with aHUS before age 1 year, have persistent hypertension, hematuria and proteinuria (sometimes in the nephrotic range), and develop chronic kidney disease with age. DGKE is found in endothelium, platelets and podocytes. Arachidonic acid–containing diacylglycerols (DAG) activate protein kinase C (PKC), which promotes thrombosis, and DGKE normally inactivates DAG signaling. We infer that loss of DGKE function results in a prothrombotic state. These findings identify a new mechanism of pathologic thrombosis and kidney failure and have immediate implications for treating individuals with aHUS.